JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2004; 43:1383-1387, doi:10.1016/j.jacc.2003.10.063
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Panchal, V. R.
Right arrow Articles by March, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Panchal, V. R.
Right arrow Articles by March, K. L.

Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease

Vipul R. Panchal, MD*, Jalees Rehman, MD*, Anne T. Nguyen, MS*, John W. Brown, MD{dagger}, Mark W. Turrentine, MD{dagger}, Yousuf Mahomed, MD{dagger} and Keith L. March, MD, PhD*,*

* Department of Medicine, Krannert Institute of Cardiology, Indianapolis, Indiana, USA
{dagger} Department of Surgery, Thoracic Surgery Section, Indiana University School of Medicine, Indianapolis, Indiana, USA



View larger version (35K):

[in a new window]
  		Figure 1 Vascular endothelial growth factor (VEGF) and endostatin levels in patients grouped with respect to gender, presence or absence of diabetes mellitus (DM), acute coronary syndrome (ACS) (present or absent), and ejection fraction (EF) (<35% or >35%). There are no statistically significant differences shown in either VEGF or endostatin with respect to any of these factors.

 


View larger version (22K):

[in a new window]
  		Figure 2 Vascular endothelial growth factor (VEGF) and endostatin levels in patients without angiographically visible collaterals (Rentrop grade 0) versus those with robust angiographically visible colaterals (Rentrop grade 3). Although VEGF is not different between these populations, endostatin is reduced by 40%, with strong significance, in the patient group that has manifested the growth of prominent collaterals.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2004 by the American College of Cardiology Foundation.